Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.
S Vasikaran, R Eastell, O Bruyère...
https://pubmed.ncbi.nlm.nih.gov/21184054/Actively Recruiting
Led by Tufts Medical Center · Updated on 2026-10-26
60
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are evaluating whether veverimer can reduce urinary net acid excretion and bone breakdown in adults aged 50 and older who have osteopenia, a condition where bone density is lower than normal but not low enough to be osteoporosis. This phase 1, prevention-focused clinical trial aims to understand how different doses of veverimer compare to placebo in reducing acid excretion and affecting bone health and physical performance. Participants will be randomly assigned to receive either 9 grams of veverimer daily, 9 grams every other day, or a placebo powder mixed into water for 8 weeks. The study includes 8 clinic visits, including a screening visit, during which participants will take the study powder and keep a diary to track medication use. The trial compares effects on acid excretion, bone resorption and formation, and physical performance. Throughout the study, participants will have urine and blood tests at multiple time points to measure acid levels, serum bicarbonate, potassium, and bone markers. The primary outcome is the change in 24-hour urinary net acid excretion measured at screening, week 2, week 8, and one day after week 8. Safety and other bone-related markers will also be monitored. Participants will be followed for a total of 8 weeks of treatment with regular clinic visits and assessments.
CONDITIONS
Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia
E
Elise Danico, MS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tufts Medical Center
Lead Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Veverimer 9 g daily (investigational) | Veverimer 9 g every other day (investigational) | Dietary calcium + vitamin D and lifestyle measures (contextual) |
|---|---|---|---|
| What it is | An investigational oral powder containing 9 g of veverimer taken daily for 8 weeks to reduce net acid excretion and bone resorption. | An investigational oral powder containing 9 g of veverimer taken every other day for 8 weeks to reduce net acid excretion and bone resorption. | Guidelines for osteopenia emphasize adequate calcium intake, vitamin D supplementation, weight‑bearing exercise, and lifestyle measures, which are the usual non‑drug approach. |
| Role in trial | Assigned investigational treatment arm receiving daily dosing. | Assigned investigational treatment arm receiving every‑other‑day dosing. | Represents the typical patient management strategy outside the trial, though not tested here. |
| Primary use | Studied to decrease net acid excretion and bone resorption markers in adults with osteopenia. | Studied to decrease net acid excretion and bone resorption markers in adults with osteopenia with alternate‑day dosing. | Used to help reduce fracture risk by supporting bone health through nutrition and physical activity. |
| How it is given or performed | Powder mixed into water taken orally once daily for eight weeks. | Powder mixed into water taken orally every other day for eight weeks. | Taken or performed as usual daily dietary intake and physical activity during routine care. |
| Evidence status | Efficacy to be determined; trial will measure changes in acid excretion and bone resorption markers at 2 and 8 weeks. | Efficacy to be determined; same markers measured on an alternate‑day dosing schedule. | Non‑drug lifestyle and supplements are commonly accepted first‑line for low‑risk osteopenia, with limited fracture prevention evidence in low‑risk individuals. |
| Important limitations | Short duration (8 weeks) and surrogate markers may not predict fracture risk or long‑term bone outcomes. | Same limitation applies: short duration and surrogate endpoints may not reflect long‑term benefit. | Lifestyle and supplementation may not substantially reduce fracture risk unless high‑risk patients are identified and managed pharmacologically. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 weeks
Participants take veverimer or placebo powder mixed with water daily or every other day for 8 weeks. They keep a medication diary and attend clinic visits for assessment.
7 visits including intermediate checkups
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Have more questions? Get in touch with our team for quick support
S Vasikaran, R Eastell, O Bruyère...
https://pubmed.ncbi.nlm.nih.gov/21184054/Svetlana V Komarova, Alexey Pereverzev, Jonathan W Shum...
https://pubmed.ncbi.nlm.nih.gov/15695591/Sigrid Jehle, Henry N Hulter, Reto Krapf
https://pubmed.ncbi.nlm.nih.gov/23162100/Donald E Wesson, Vandana Mathur, Navdeep Tangri...
https://pubmed.ncbi.nlm.nih.gov/30857647/L Frassetto, R C Morris, A Sebastian
https://pubmed.ncbi.nlm.nih.gov/8989270/Russel Burge, Bess Dawson-Hughes, Daniel H Solomon...
https://pubmed.ncbi.nlm.nih.gov/17144789/David A Bushinsky, Nancy S Krieger
https://pubmed.ncbi.nlm.nih.gov/35351460/Kendall F Moseley, Connie M Weaver, Lawrence Appel...
https://pubmed.ncbi.nlm.nih.gov/22991267/T R Arnett, D W Dempster
https://pubmed.ncbi.nlm.nih.gov/3720660/Mary P Kotlarczyk, Subashan Perera, Neil M Resnick...
https://pubmed.ncbi.nlm.nih.gov/32458096/Tufts Medical Center
Lead Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborating Sponsor